Alcon: Glaucoma trials

The registry lists 156 Glaucoma studies with Alcon as lead sponsor. 0 are open to participants now and 70 have results posted.

Phase 1 3Phase 2 37Phase 3 52Phase 4 51No phase 17(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rocklatan® EvaluationCompletedNCT05283395Phase 4Results posted
• Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04620135Phase 3Results posted
• Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanCompletedNCT03844945Phase 2Results posted
• Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world SettingCompletedNCT03808688Phase 4Results posted
• Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionCompletedNCT03310580Phase 2Results posted
• Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionCompletedNCT03284853Phase 3Results posted
• Post Approval Study of the CyPass SystemTerminatedNCT03273907Not applicableResults posted
• Hydrus Microstent for Refractory Open-Angle GlaucomaCompletedNCT03267134Not applicableResults posted
• Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT03233308Phase 2Results posted
• 24-hr Intraocular Pressure Control With SIMBRINZA ®CompletedNCT02770248Phase 4Results posted
• A Three Part Study of MGV354 in Ocular Hypertension or GlaucomaCompletedNCT02743780Phase 1/2Results posted
• A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS TrialCompletedNCT02700984Not applicableResults posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02674854Phase 3Results posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02558400Phase 3Results posted
• Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02558374Phase 3Results posted
• Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedNCT02339584Phase 3Results posted
• Alcon® Ex-PRESS® Glaucoma Filtration Device in Japanese PatientsCompletedNCT02246777Not applicableResults posted
• Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02246764Phase 3Results posted
• Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionCompletedNCT02207621Phase 3Results posted
• Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02207491Phase 3Results posted
• 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02140060Phase 2Results posted
• Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressureCompletedNCT02057575Phase 2Results posted
• Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract SurgeryCompletedNCT02024464Not applicableResults posted
• Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic EyesCompletedNCT02023242Not applicableResults posted
• Efficacy of Travoprost/Timolol for Uncontrolled Intraocular PressureCompletedNCT02003391Phase 4Results posted
• Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension GlaucomaCompletedNCT01995136Phase 4Results posted
• Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01978600Phase 4Results posted
• Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueCompletedNCT01937312Phase 4Results posted
• Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®CompletedNCT01937299Phase 4Results posted
• Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular PressureCompletedNCT01731002Phase 2Results posted
• An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®CompletedNCT01664039Phase 4Results posted
• Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma PatientsCompletedNCT01658839Phase 1Results posted
• Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma PatientsCompletedNCT01652664Phase 3Results posted
• Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)CompletedNCT01539239Not applicableResults posted
• Study of AR-13324 in Patients With Elevated Intraocular PressureCompletedNCT01528787Phase 2Results posted
• Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin AmericaCompletedNCT01518244Phase 4Results posted
• Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in BrazilTerminatedNCT01514734Phase 4Results posted
• Efficacy of Changing to TRAVATAN® From Prior TherapyCompletedNCT01510145Phase 4Results posted
• Efficacy of Changing to TRAVATAN® From Prior TherapyCompletedNCT01493427Phase 4Results posted
• AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular PressureCompletedNCT01484951Phase 4Results posted
• Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)CompletedNCT01464424Phase 4Results posted
• Travoprost 3-Month Safety and Efficacy StudyCompletedNCT01453855Phase 3Results posted
• A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01426867Phase 2Results posted
• Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in CanadaCompletedNCT01415401Phase 4Results posted
• Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01357616Phase 3Results posted
• Patient Preference Comparison of AZARGA Versus COSOPTCompletedNCT01340014Phase 4Results posted
• Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on TimololCompletedNCT01336569Phase 4Results posted
• Efficacy of Changing to DUOTRAV® From Prior TherapyCompletedNCT01327599Phase 4Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01310777Phase 3Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01309204Phase 3Results posted
• Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%CompletedNCT01297920Phase 3Results posted
• Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01297517Phase 3Results posted
• Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyCompletedNCT01263444Phase 4Results posted
• Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00966940Phase 4Results posted
• Safety and Efficacy of Brinzolamide/Brimonidine Fixed CombinationTerminatedNCT00961649Phase 2Results posted
• Efficacy Study of Travoprost APS Versus TRAVATANCompletedNCT00848536Phase 3Results posted
• Circadian Ocular Perfusion Pressure and Ocular Blood FlowCompletedNCT00800540Phase 4Results posted
• Examination of Ocular Surface Effects With Administration of Travatan Z and XALATANCompletedNCT00798759Phase 4Results posted
• Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular HypertensionCompletedNCT00763061Phase 4Results posted
• Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)CompletedNCT00762645Phase 4Results posted
• Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthCompletedNCT00761319Phase 3Results posted
• A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a ProstaglandinCompletedNCT00759941Phase 4Results posted
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)TerminatedNCT00758342Phase 4Results posted
• Effects of Travatan Z and Xalatan on Ocular Surface HealthCompletedNCT00708422Phase 4Results posted
• Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00690794Phase 3Results posted
• A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00527592Phase 4Results posted
• Adherence Assessment With Travalert Dosing AidCompletedNCT00508469Phase 4Results posted
• A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular HypertensionCompletedNCT00471380Phase 4Results posted
• Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00471068Phase 4Results posted
• A Long-term Safety Study of Once-daily TravatanCompletedNCT00051168Phase 3Results posted
• Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionCompletedNCT07082816Phase 3
• Next Generation RocklatanCompletedNCT06441643Phase 2
• EX-PRESS® P-50 and EX-PRESS® P-200CompletedNCT06119178
• Safety and Effectiveness of the Hydrus MicrostentTerminatedNCT05198297Not applicable
• Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAGCompletedNCT03065036Phase 1/2
• Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.CompletedNCT01818115Not applicable
• A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedNCT01789736Phase 2
• A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedNCT01699464Phase 2
• Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in RussiaWithdrawnNCT01696383Phase 4
• Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior TherapyTerminatedNCT01514721Phase 4
• Travacom Post Marketing Surveillance StudyWithdrawnNCT01510132Phase 4
• A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic SolutionTerminatedNCT01485822
• AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedNCT01474135Phase 2
• Patient Preference Comparison of AZARGA Versus COSOPT in Patients With GlaucomaCompletedNCT01471158Phase 4
• Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%WithdrawnNCT01452009Phase 3
• 24-hour Efficacy of AR-12286CompletedNCT01330979Phase 2
• Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412CTerminatedNCT01312454Phase 2
• AR-12286 in Combination With LatanoprostCompletedNCT01302249Phase 2
• Divided Dose of TRAVATAN®CompletedNCT01298687Phase 2
• Safety and Efficacy of Changing to DuoTrav From Prior TherapyCompletedNCT01230736Phase 4
• Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular HypertensionCompletedNCT01111890Phase 4
• Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular PressureCompletedNCT01060579Phase 2
• ELAZOP Switching Study in KoreaCompletedNCT01055366Phase 4
• Efficacy and Safety of Adding Azarga to Prostaglandin MonotherapyCompletedNCT00966576Phase 4
• Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00928590Phase 3
• Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface HealthCompletedNCT00892762Phase 3
• Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00872651Phase 3
• Safety and Efficacy Study of DuoTrav APS Versus DuoTravWithdrawnNCT00862472Phase 3
• DuoTrav® Eye Drops As Replacement Therapy ProgramCompletedNCT00828906Phase 4
• A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00788541Phase 2